by Congenital Hyperinsulinism Treatment refers to medical procedures and medications used to treat congenital hyperinsulinism (CHI), a rare genetic disorder characterized by inappropriate and excessive insulin secretion resulting in abnormally low blood sugar levels (hypoglycemia). The global congenital hyperinsulinism treatment market sees rising demand for drugs and surgical options to manage hypoglycemia in affected newborns and infants. Treatment involves use of medication such as diazoxide and octreotide to reduce insulin levels or partial pancreatectomy surgery to remove part of the pancreas responsible for excess insulin production.
The global Congenital Hyperinsulinism Treatment Market is estimated to be valued at US$ 217.74 Mn in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising number of surgical procedures for congenital hyperinsulinism is a key trend fuelling the global congenital hyperinsulinism treatment market growth over the forecast period. Surgical removal of part of the pancreas (partial pancreatectomy) is required for about 40% to 60% of CHI patients who do not respond sufficiently to medical management. With increasing diagnosis of CHI cases, surgical referrals and procedures have witnessed strong growth over the past few years. Moreover, surgical techniques are also advancing with minimally invasive laparoscopic approaches gaining popularity over traditional open pancreatectomies due to benefits such as less postoperative pain, shorter hospital stays and faster recovery times. This is expected to further drive the uptake of partial pancreatectomy procedures for CHI treatment during the forecast period.
SWOT Analysis
Strength: The market comprises a few established players with strong product pipelines for congenital hyperinsulinism treatment. The current treatment options in the market are effective in controlling blood sugar levels.
Weakness: High costs associated with congenital hyperinsulinism treatments pose affordability challenges. Lack of awareness about congenital hyperinsulinism condition in developing regions limits market growth.
Opportunity: Rising healthcare expenditure in emerging economies opens up new opportunities. Growing initiatives to spread awareness about rare diseases present opportunities.
Threats: Stringent regulatory policies for new drug approvals can delay product launches. Unfavourable reimbursement policies in some countries hamper market revenues.
Key Takeaways
The Global Congenital Hyperinsulinism Treatment Market Size is expected to witness high growth. The market size is projected to reach US$ 217.74 Mn by 2024, registering a CAGR of 6.2% during the forecast period.
Regional analysis: North America dominates the market currently due to advanced healthcare infrastructure and high healthcare spending. The region accounts for over 40% of global market revenues. Asia Pacific is expected to witness fastest growth aided by rising incomes, healthcare reforms and expanding medical tourism industry in the region.
Key players operating in the congenital hyperinsulinism treatment market are Medtronic, Ace-medical, VOGT MEDICAL, BD (Becton, Dickinson and Company), Smiths Medical, Inc., Samtronic., CODAN ARGUS AG, B. Braun SE, Medical Components, Inc., Fresenius SE & Co. KGaA, Baxter, EuroLife Healthcare Pvt. Ltd, and Micrel Medical Devices.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
